Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company’s lead program, buloxibutid, is a first-in-class oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. Vicore is publicly listed on the Nasdaq Stockholm exchange with the ticker VICO.
Looking for a particular Vicore Pharma AB employee's phone or email?
Vicore Pharma AB Questions
The Vicore Pharma AB annual revenue was $9.5 million in 2026.
Mikael Nygård is the COO of Vicore Pharma AB.
42 people are employed at Vicore Pharma AB.
Vicore Pharma AB is based in Stockholm, Stockholm County.
The NAICS codes for Vicore Pharma AB are [54171, 325, 541711, 5417, 54, 541, 32].
The SIC codes for Vicore Pharma AB are [28, 283, 2834].
Top Vicore Pharma AB Employees
-
2
-
Ahmed Mousa
Chief Executive Officer at Vicore Pharma AB
Boston, MA, US25+ -
Jimmie Hofman
Chief Business Officer at Vicore Pharma AB
Stockholm, SE11 -
22
-
22
-
Bernt van Den Blink
Chief Medical Officer at Vicore Pharma AB
Amsterdam, NH, NL2 -
34
-
Rohit Anand
Vice President Finance at Vicore Pharma AB
Boston, MA, US25+
Related Companies
